Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how to access lanadelumab through the province's Expensive

We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its February Ontario Drug Benefit (ODB) formulary update,

Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro) through the province's Drug Plan. HAE Canada

We wanted to let our members know that starting February 1st, 2021, CSL Behring patient support programs (Hizentra™ CARE Program, and Berinert® Assistance Program) will be streamlined into one program called CSL Behring PLUS+. Patients will

Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss HAE patients and the COVID vaccine. We encourage everyone to please watch this short video that discusses how having HAE

We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug Benefit List. Alberta is the first province

Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA)

We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab (Takhzyro) and soon HAE patients in Quebec